Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · IEX Real-Time Price · USD
5.66
-0.15 (-2.58%)
Apr 24, 2024, 4:00 PM EDT - Market closed
Cytek Biosciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Cytek Biosciences stock have an average target of 9.00, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 59.01% from the current stock price of 5.66.
Analyst Consensus: Buy
* Price targets were last updated on Mar 6, 2024.
Analyst Ratings
The average analyst rating for CTKB stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $10 | Buy | Maintains | $11 → $10 | +76.68% | Mar 6, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +76.68% | Feb 29, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $9 | Buy | Initiates | $9 | +59.01% | Dec 14, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $8 → $7 | Hold | Maintains | $8 → $7 | +23.67% | Nov 9, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $13 → $8 | Hold | Maintains | $13 → $8 | +41.34% | Oct 24, 2023 |
Financial Forecast
Revenue This Year
212.02M
from 193.02M
Increased by 9.85%
Revenue Next Year
251.99M
from 212.02M
Increased by 18.85%
EPS This Year
-0.03
from -0.09
EPS Next Year
0.10
from -0.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 220.5M | 280.1M | 324.1M |
| Avg | 212.0M | 252.0M | 282.4M |
| Low | 201.1M | 220.1M | 237.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 14.2% | 32.1% | 28.6% |
| Avg | 9.8% | 18.9% | 12.1% |
| Low | 4.2% | 3.8% | -5.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.03 | 0.22 | 0.37 |
| Avg | -0.03 | 0.10 | 0.22 |
| Low | -0.10 | -0.02 | 0.11 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | 254.4% |
| Avg | - | - | 109.8% |
| Low | - | - | 4.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.